MicroPort Scientific Corporation

SZSC:853 Stock Report

Market Cap: HK$12.2b

MicroPort Scientific Valuation

Is 853 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 853 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 853 (HK$6.66) is trading below our estimate of fair value (HK$13.19)

Significantly Below Fair Value: 853 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 853?

Other financial metrics that can be useful for relative valuation.

853 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA-19x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 853's PS Ratio compare to its peers?

The above table shows the PS ratio for 853 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
6699 Angelalign Technology
5.9x15.3%HK$11.0b
1302 LifeTech Scientific
5.5x21.5%HK$7.7b
1789 AK Medical Holdings
4.9x24.9%HK$5.9b
2291 LEPU ScienTech Medical Technology (Shanghai)
13.9xn/aHK$6.2b
853 MicroPort Scientific
1.5x15.3%HK$12.2b

Price-To-Sales vs Peers: 853 is good value based on its Price-To-Sales Ratio (1.5x) compared to the peer average (7.6x).


Price to Earnings Ratio vs Industry

How does 853's PE Ratio compare vs other companies in the HK Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a38.9%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a38.9%
n/an/an/a
No more companies

Price-To-Sales vs Industry: 853 is good value based on its Price-To-Sales Ratio (1.5x) compared to the Hong Kong Medical Equipment industry average (3.4x).


Price to Sales Ratio vs Fair Ratio

What is 853's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

853 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: 853 is good value based on its Price-To-Sales Ratio (1.5x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 853 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$6.66
HK$8.92
+34.0%
52.5%HK$21.02HK$5.78n/a8
Nov ’25HK$6.48
HK$8.88
+37.0%
52.8%HK$21.00HK$5.78n/a8
Oct ’25HK$7.88
HK$8.88
+12.7%
52.6%HK$20.94HK$5.79n/a8
Sep ’25HK$4.94
HK$11.71
+137.1%
55.0%HK$24.20HK$6.69n/a8
Aug ’25HK$5.30
HK$11.73
+121.3%
54.9%HK$24.20HK$6.71n/a8
Jul ’25HK$5.27
HK$12.14
+130.4%
51.0%HK$24.17HK$6.69n/a8
Jun ’25HK$5.80
HK$12.62
+117.6%
55.2%HK$24.91HK$6.69n/a8
May ’25HK$6.29
HK$13.34
+112.0%
54.1%HK$25.00HK$6.71n/a7
Apr ’25HK$6.57
HK$13.94
+112.1%
49.1%HK$24.98HK$7.19n/a8
Mar ’25HK$7.40
HK$16.79
+126.9%
36.4%HK$24.97HK$8.40n/a8
Feb ’25HK$5.78
HK$17.80
+207.9%
29.4%HK$24.97HK$9.49n/a8
Jan ’25HK$8.42
HK$18.88
+124.2%
24.2%HK$24.93HK$9.48n/a8
Dec ’24HK$12.54
HK$18.89
+50.6%
24.2%HK$24.95HK$9.48n/a8
Nov ’24HK$12.18
HK$18.89
+55.1%
24.2%HK$24.95HK$9.48HK$6.488
Oct ’24HK$11.84
HK$18.89
+59.5%
24.2%HK$24.95HK$9.48HK$7.888
Sep ’24HK$13.42
HK$21.76
+62.1%
28.4%HK$30.17HK$9.50HK$4.949
Aug ’24HK$15.36
HK$23.01
+49.8%
26.7%HK$29.99HK$9.48HK$5.309
Jul ’24HK$14.16
HK$24.74
+74.7%
26.0%HK$32.30HK$9.49HK$5.279
Jun ’24HK$13.80
HK$25.35
+83.7%
20.5%HK$32.31HK$14.49HK$5.809
May ’24HK$17.28
HK$25.35
+46.7%
20.5%HK$32.32HK$14.50HK$6.299
Apr ’24HK$18.46
HK$25.27
+36.9%
19.0%HK$32.32HK$15.58HK$6.579
Mar ’24HK$22.75
HK$25.34
+11.4%
19.8%HK$32.32HK$15.58HK$7.408
Feb ’24HK$26.30
HK$23.51
-10.6%
18.7%HK$29.85HK$15.50HK$5.788
Jan ’24HK$20.55
HK$26.04
+26.7%
48.8%HK$57.40HK$15.50HK$8.428
Dec ’23HK$18.72
HK$26.17
+39.8%
48.8%HK$57.71HK$15.47HK$12.548
Nov ’23HK$17.10
HK$25.76
+50.6%
51.7%HK$58.00HK$11.50HK$12.188

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies